Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | MDM4 | O15151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31098371 | 1.00 | CASP3 (0.45) | CASP3KMT2APIN1MDM4TP53 | |
| SCHEMBL21432488 | 1.00 | CASP3 (0.45) | CASP3KMT2APIN1MDM4TP53 | |
| SCHEMBL21416088 | 1.00 | CASP3 (0.45) | CASP3KMT2APIN1MDM4TP53 | |
| SCHEMBL21403411 | 1.00 | CASP3 (0.45) | CASP3KMT2APIN1MDM4TP53 | |
| SCHEMBL29403817 | 1.00 | CASP3 (0.45) | CASP3KMT2APIN1MDM4TP53 | |
| SCHEMBL28522099 | 0.88 | CASP3 (0.48) | CASP3KMT2APIN1MDM4TP53 | |
| SCHEMBL8210873 | 0.88 | CASP3 (0.48) | CASP3KMT2APIN1MDM4TP53 | |
| SCHEMBL30883312 | 0.87 | CASP3 (0.50) | CASP3KMT2APIN1MDM4TP53 | |
| SCHEMBL29402992 | 0.87 | CASP3 (0.50) | CASP3KMT2APIN1MDM4TP53 | |
| SCHEMBL19944056 | 0.84 | CASP3 (0.53) | CASP3KMT2APIN1MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112585116-B | Synthesis of (2S, 3R, 4R) -4, 5-dihydroxyisoleucine and derivatives thereof | 海德堡医药研究有限责任公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20220298204-A1 | SYNTHESIS OF A-AMANITIN AND ITS DERIVATIVES | PURE BIOORGANICS SIA (LV) | 2022-09-22 | — | — | US | disclosed |
| EP-3994146-A1 | SYNTHESIS OF A-AMANITIN AND ITS DERIVATIVES | Pure Bioorganics SIA (LV) | 2022-05-11 | — | — | EP | disclosed |
| CN-114080395-A | Synthesis method of alpha-amanitine and derivatives thereof | 纯生物有机有限公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-112585116-A | Synthesis of (2S, 3R, 4R) -4, 5-dihydroxyisoleucine and derivatives thereof | 海德堡医药研究有限责任公司 | 2021-03-30 | — | — | CN | disclosed |
| EP-3792250-A1 | SYNTHESIS OF ALPHA-AMANITIN AND ITS DERIVATIVES | Pure Bioorganics SIA (LV) | 2021-03-17 | — | — | EP | disclosed |
| WO-2021004973-A1 | SYNTHESIS OF A-AMANITIN AND ITS DERIVATIVES | PURE BIOORGANICS SIA (LV) | 2021-01-14 | — | — | WO | disclosed |
| EP-3546447-A1 | SYNTHESIS OF (2S,3R,4R)-4,5-DIHYDROXYISOLEUCINE AND DERIVATIVES | Heidelberg Pharma GmbH (DE) | 2019-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298204-A1 | SYNTHESIS OF A-AMANITIN AND ITS DERIVATIVES | MEP1A, MEP1B, MANBA | CASP3 3777/4885KMT2A 2218/4885PIN1 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.